Targeted drug trial offers hope for aggressive brain cancer recurrence
NCT ID NCT03561870
Summary
This study tested whether the drug olaparib could help control recurrent high-grade brain tumors that have a specific genetic change called an IDH mutation. The trial involved 35 adults in France whose brain cancer had returned after standard treatments like radiation and chemotherapy. Researchers gave participants olaparib daily to see if it could keep the cancer from growing for at least six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT IDH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospices Civils de Lyon
Bron, France
Conditions
Explore the condition pages connected to this study.